Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ArTCell

Financiado

Bottom-up manufacturing of artificial anti-tumor T cells

T cells play a central role in anti-tumor immune protection. While their ability to target and eliminate emerging tumor cells is increasingly recognized, fully-established tumors can efficiently evade T cell response. Significant... ver más

31/01/2029

KU Leuven

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-09

HORIZON-EIC-2023-PATHFINDEROPEN-01-01: EIC Pathfinder Open Scope:

I+D

Cerrada hace 1 año

0% 100% 100%

4 Participantes

KU Leuven

1.67M€ | Lider

UNIVERSITAIR MEDISCH CENTRUM...

678.81K€ | Participante

TLS

546.50K€ | Participante

INSTYTUT MEDYCYNY DOSWIADCZA...

499.88K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SynT Generation, validation and use of a synthetic reporter of CA... 150K€ Cerrado

PID2019-109546RA-I00 CELULAS T GENETICAMENTE MODIFICADAS PARA EXPRESAR RECEPTORES... 163K€ Cerrado

CATCH Novel T cell therapies against lymphocytic leukaemia 150K€ Cerrado

RYC2018-024442-I Chimeric Antigen Receptor (CAR)-modified T cells for the tre... 309K€ Cerrado

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

T2Lead Define a lead candidate for clinical development of a novel... 150K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2023-10-09
Fecha Fin: 2029-01-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto T cells play a central role in anti-tumor immune protection. While their ability to target and eliminate emerging tumor cells is increasingly recognized, fully-established tumors can efficiently evade T cell response. Significant efforts spanning several decades of research have been made to develop T cell-based therapies manufactured from donor-derived T cells. The use of tumor-directed T cells engineered to express chimeric antigen receptors (CARs) represents, to date, one of the most successful applications for treatment of chemoresistant cancers. However, several major drawbacks, including economic factors, suboptimal functioning and life-threatening side effects, are still hindering the full potential of T cell-based therapies. To address this issue, we aim to generate Artificial T cells (ArTCell) that will mimic the anti-tumor function of a T cell-based therapy but in a safer, more efficient and less expensive product. ArTCells will incorporate two key features of activated T cells into Giant Unilamellar Vesicles (GUVs): the specificity of tumor cell recognition and the cytotoxic activity achieved through death ligands and cytolytic proteins. Functionalization of the GUVs will be confirmed by immunofluorescent labelling of membrane proteins (i.e., TRAIL, LFA-1 and CAR) and detection with flow cytometry. The morphology of ArTCell will be monitored via cryo-EM, SEM, and confocal microscopy. The ability of ArTCell to target and kill tumour cells will be thoroughly validated in vitro by a combination of functional and high resolution live imaging assays as well as in vivo with two cell line- and patient-xenografts mouse models. The ArTCell could allow to circumvent many of the current technological limitations that hinder a more wide-spread applicability of cell-based therapies, without being subject to tumor-mediated inactivation

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores